Al18F-NOTA-FAPI

Phase 3Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-NOTA-FAPI is one of 13 small molecule programs targeting Malignant Tumors. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant TumorsRecruiting

Malignant TumorsPhase 3

Recruiting

Competition

Competitive Landscape

18 competitors in Malignant Tumors

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 2

2 2

Beyfortus

BeiGene

Phase 2

2 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

3 4

Taxotere

AAvyxa

Phase 2

1 5

Ifinatamab Deruxtecan

Daiichi Sankyo

Phase 2

1 6

LBL-007

BeiGene

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 1

2 8

Abraxane

Bristol-Myers Squibb

Phase 1

1 9

Al18F-NOTA-FAPI

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

1 10

Anti-PD-1 Antibody

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malignant Tumors1 trial

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

Recruiting·—·Phase 2/3·NCT05749302·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Al18F-NOTA-FAPI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Al18F-NOTA-FAPI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Al18F-NOTA-FAPI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-NOTA-FAPI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malignant Tumors1 trial

References

Drug Info

Quick Facts

Related News